AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32293523
Drug: Benznidazole (BNZ)
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole (BNZ) 300 mg/day for 60 days (comparator arm)
Trial: 35084435
Drug: BQ-123 (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ-123 (selective ETA receptor antagonist)
Trial: 33252549
Drug: 30 tablets
RxNorm normalized name: nitrogen 30 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 tablets of hydrocodone/acetaminophen 10 to 325 mg
Trial: 33252549
Drug: 60 tablets
RxNorm normalized name: Polysorbate 60
DrugBank: Polysorbate 60 (DB14153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 tablets of hydrocodone/acetaminophen 10 to 325 mg
Trial: 33177393
Drug: 0.005% calcipotriol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005% calcipotriol ointment
Trial: 33843675
Drug: Blue-green (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue-green (500 nm) light therapy for SCD treatment
Trial: 33843675
Drug: Blue-green (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue-green (500 nm) light therapy for aMCI treatment
Trial: 34129743
Drug: Standardised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised exercise programme for the jaw and orofacial muscles and individualised oral hygiene programme
Trial: 89344702
Drug: Three reduced
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three reduced doses of Merck Sharp and Dohme (MSD) H‐B Vax plasma derived vaccine (2 micrograms each) given intramuscularly at monthly intervals.
Trial: 33573696
Drug: Nilavembu Kudineer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilavembu Kudineer (60 Ml Morning and Night after Food, along with standard Allopathy Treatment for 10 days)
Trial: 33573696
Drug: Kaba Sura
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaba Sura Kudineer (60 Ml Morning and Night after Food, along with standard Allopathy Treatment for 10 days)
Trial: 33573696
Drug: Decaffeinated Tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated Tea (Placebo - 60 Ml Morning and Night after Food, along with standard Allopathy Treatment for 10 days)
Trial: 32424455
Drug: Pelvic Organ
RxNorm normalized name: ProVate Pelvic Organ Prolapse Supports (61mm)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic Organ Prolapse Suspension (POPS)
Trial: 34714139
Drug: RI aqueous
RxNorm normalized name: Ri-Mag Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RI aqueous extract fluid of 1.78 mg/mL
Trial: 34714139
Drug: RI aqueous
RxNorm normalized name: Ri-Mag Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RI aqueous extract fluid of 2.66 mg/mL
Trial: 39028879
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (DOAC)
Trial: 33852339
Drug: PARP inhibitors
RxNorm normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARP inhibitors (PARPi) - olaparib and talazoparib, provided in capsule form
Trial: 33147665
Drug: Ingenol disoxate
RxNorm normalized name: Ingenol disoxate
DrugBank: Ingenol disoxate (DB15109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingenol disoxate gel (IngDsx, 0.018% for face/chest; 0.037% for scalp)
Trial: 34162825
Drug: General awareness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General awareness of oral cancer
Trial: 34162825
Drug: Knowledge of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge of risk factors for oral cancer
Trial: 32525235
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy Continuation (MBCT-C) for 26 weeks
Trial: 32108029
Drug: Low-Carbohydrate Diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Carbohydrate Diet (LCD) - instructed to eat <20 g/carbs/day
Trial: 32293810
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (Group C)
Trial: 34179755
Drug: Lidocaine trigger
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine trigger point injection
Trial: 34179755
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline interfascial injection
Trial: 616117791
Drug: Liposomal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal spray containing phosphatidylcholine (PC) (Tears again, BioRevive)
Trial: 616117791
Drug: Control saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control saline spray
Trial: 32216042
Drug: Chemotherapy-only group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-only group
Trial: 33223272
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment (specifics not provided)
Trial: 35351535
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg/day for 24 weeks
Trial: 37314275
Drug: Family-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based treatment
Trial: 32432326
Drug: Intrauterine insemination
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine insemination (IUI) with timing from hCG injection
Trial: 35372576
Drug: Peripheral Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral Intravenous Thrombolysis (PIT)
Trial: 34528282
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg PMO once daily
Trial: 34528282
Drug: 360 mg
RxNorm normalized name: aspirin 360 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg PMO twice daily
Trial: 34528282
Drug: 540 mg
RxNorm normalized name: lecithin 540 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 540 mg PMO thrice daily
Trial: 33964572
Drug: ALP 250
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ALP 250 mg + EVE 2.5 mg
Trial: 33964572
Drug: ALP 200
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ALP 200 mg + EVE 2.5 mg + EXE 25 mg
Trial: 33832878
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) plus Best Supportive Care (BSC)
Trial: 33832878
Drug: Ramucirumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab (8 mg/kg) plus erlotinib (25 mg/day)
Trial: 32638373
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine treatment
Trial: 32638373
Drug: Cytarabine as
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine as a single agent
Trial: 32629668
Drug: Low-dose glucocorticoids
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose glucocorticoids + methotrexate + hydroxychloroquine
Trial: 35725261
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nurse-led volunteer support and technology-driven pain assessment
Trial: 33983564
Drug: 8% capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% capsaicin cutaneous patch
Trial: 33826656
Drug: Metformin (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (doses ranging from 500-1500mg)
Trial: 33826656
Drug: Physiologically based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologically based pharmacokinetic (PBPK) model for metformin in humans
Trial: 33826656
Drug: PBPK model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBPK model for metformin in mice
Trial: 33115543
Drug: Imatinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (400 mg orally daily for 14 days)
Trial: 36189751
Drug: IV push
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV push administration of levetiracetam
Trial: 36189751
Drug: IV piggyback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV piggyback administration of levetiracetam
Trial: 38421679
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid injection
Trial: 36884302
Drug: Dabrafenib monotherapy
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib monotherapy
Trial: 34902262
Drug: SOC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC plus a single subcutaneous dose of sarilumab 400 mg
Trial: 34902262
Drug: SOC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC plus a single subcutaneous dose of sarilumab 200 mg
Trial: 33380581
Drug: Hydrogen-rich gas
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen-rich gas (HG) inhalation during a 60-minute recovery phase after exercise
Trial: 33380581
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation (ambient air) during a 60-minute recovery phase after exercise
Trial: 34928519
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml thin liquid bolus
Trial: 34928519
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml thin liquid bolus
Trial: 34928519
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml thin liquid bolus
Trial: 34928519
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml thick liquid bolus
Trial: 32312337
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (containing at least 250 mg DHA and at least 60 mg EPA)
Trial: 35043869
Drug: Ultrasound-guided bilateral
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided bilateral erector spinae plane block combined with intravenous patient-controlled analgesia (iv PCA)
Trial: 35043869
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia (iv PCA) alone
Trial: 34229862
Drug: Levobupivacaine 0.25%
RxNorm normalized name: levobupivacaine 0.25% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.25% plus dexmedetomidine 1 μg.kg‐1
Trial: 34913825
Drug: Econazole 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Econazole 250 mg
Trial: 34913825
Drug: Econazole 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Econazole 500 mg
Trial: 34913825
Drug: Econazole 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Econazole 1000 mg
Trial: 33644986
Drug: Soft-tissue mobilization
RxNorm normalized name: methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soft-tissue mobilization therapy and 20 spinal mobility exercises
Trial: 32338931
Drug: Exposure-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based cognitive therapy (EBCT)
Trial: 32811734
Drug: Trimodal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimodal therapy consisting of 2% Nitroglycerine (NTG), Hyperbaric Oxygen Therapy (HBOT), and local steroids
Trial: 32811734
Drug: Nitroglycerine (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerine (NTG) and local steroids (without HBOT)
Trial: 36309759
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg oral bosentan, twice a day for 8 weeks
Trial: 33627329
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (standard management)
Trial: 33627329
Drug: Placebo (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5% dextrose) infusion (restrictive management)
Trial: 34044534
Drug: Cyclic peptide
RxNorm normalized name: Cyclic peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic peptide inhibitors of FXIIa
Trial: 33124895
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (Levilactobacillus brevis CECT7480 and Lactoplantibacillus plantarum CECT7481), 2 tablets per day for 1 week
Trial: 34639746
Drug: CPSCoD training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPSCoD training (twice weekly for 8 weeks)
Trial: 36045965
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray combined with loratadine
Trial: 36096534
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg) every 4 weeks until worsening or unacceptable toxicity
Trial: 36183101
Drug: Aqueous crystalline
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous crystalline penicillin G (ACPG)
Trial: 39424558
Drug: Alteplase 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase 0.9 mg/kg
Trial: 39424558
Drug: Tenecteplase 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenecteplase 0.25 mg/kg
Trial: 33721689
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (active)
Trial: 33721689
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (passive)
Trial: 36841762
Drug: Liraglutide 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 3.0 mg/day
Trial: 39160110
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal oxygen therapy (HFNO)
Trial: 39111953
Drug: Sacubitril/Valsartan 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/Valsartan 200 mg twice daily
Trial: 36082663
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 mg twice daily
Trial: 32331024
Drug: AMPH EROS
RxNorm normalized name: AMPH-b
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMPH EROS 20 mg fasted
Trial: 35555189
Drug: Creatine Nitrate
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine Nitrate (CN: 5 g/day + 0.675 g/day of maltodextrin)
Trial: 33927343
Drug: Selective progesterone
RxNorm normalized name: Selective progesterone receptor modulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective progesterone receptor modulator (SPRM)
Trial: 39539664
Drug: Anticoagulant monotherapy
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant monotherapy
Trial: 32307878
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg Sustanon® (testosterone ester injections)
Trial: 32653333
Drug: Intravenous cetirizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cetirizine 10 mg
Trial: 32653333
Drug: Intravenous diphenhydramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diphenhydramine 50 mg
Trial: 35482774
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to aerobic exercise prescription (at least two-thirds of the prescribed exercise)
Trial: 38598227
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave therapy
Trial: 33666264
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care (PC) in addition to traditional care
Trial: 35044972
Drug: Topical amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical amphotericin B 0.15% plus CXL
Trial: 34818273
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin Type A (BTX) intradermal injections to the treated side of the inframammary incision
Trial: 35017306
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) for acute ischemic stroke (AIS) in patients with active cancer
Trial: 35017306
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) for acute ischemic stroke (AIS) in patients with active cancer in a palliative treatment setting
Trial: 35017306
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) for acute ischemic stroke (AIS) in patients without active cancer
Trial: 32310691
Drug: Momiai (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Momiai (500 mg capsules)
Trial: 32310691
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg capsules)
Trial: 35184324
Drug: Medication consultation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication consultation (additional consultation with a physician)
Trial: 35184324
Drug: Medication consultation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication consultation
Trial: 34795574
Drug: Virtual reality-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality-based therapy combined with conventional functional training (1 hour of functional training + 1 hour of virtual reality therapy using Armeo Spring equipment)
Trial: 35612617
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (MG) - Oral dose of UC-II (1 capsule/day)
Trial: 33530312
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral treatment with 3 g Clostridium butyricum
Trial: 33530312
Drug: No probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No probiotic treatment
Trial: 36525985
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching capsules)
Trial: 34413142
Drug: Hyoscine N‐butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine N‐butylbromide (20 mg intravenous injection)
Trial: 34413142
Drug: Loperamide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (4 mg per os)
Trial: 36322475
Drug: Dissolved tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dissolved tablet (BIC/TAF/FTC 50/200/25 mg)
Trial: 36322475
Drug: Crushed tablet
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed tablet (BIC/TAF/FTC 50/200/25 mg)
Trial: 36322475
Drug: Solid tablet
RxNorm normalized name: Corydalis solida whole extract
DrugBank: Lactobionic acid (DB16621)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid tablet (BIC/TAF/FTC 50/200/25 mg)
Trial: 35709600
Drug: Enzalutamide (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide (160 mg daily)
Trial: 33496795
Drug: Bicalutamide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide (50 mg daily)
Trial: 33496795
Drug: Enzalutamide (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide (160 mg daily) among Black patients
Trial: 33496795
Drug: Bicalutamide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide (50 mg daily) among Black patients
Trial: 33496795
Drug: Enzalutamide (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide (160 mg daily) among non-Black patients
Trial: 33496795
Drug: Bicalutamide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide (50 mg daily) among non-Black patients
Trial: 32112428
Drug: Permethrin 5%
RxNorm normalized name: PERMETHRIN 5% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permethrin 5% cream (treatment group)
Trial: 34599979
Drug: Benralizumab 30
RxNorm normalized name: benralizumab 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab 30 mg every 4 weeks for the first 3 doses, then every 8 weeks thereafter
Trial: 33964405
Drug: Intradiscal ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal ozone infiltration (plus foraminal infiltration of ozone, steroids, and anesthetic)
Trial: 33964405
Drug: Intradiscal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal oxygen infiltration (plus foraminal infiltration of oxygen, steroids, and anesthetic)
Trial: 34058081
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg dipyrone
Trial: 34058081
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tilidine/naloxone
Trial: 34058081
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tilidine/naloxone